Crossing the Valley of Death: The Translational Funding Crossing the Valley of Death: The Translational Funding and Management Gapand Management Gap
Moderator: Sharon Begley, Science Editor, Newsweek
Panelists:• Robi Blumenstein, President, CHDI Management/CHDI Foundation• Randall Carpenter, Co-Founder, President and Chief Executive Officer,
Seaside Therapeutics• Dennis Purcell, Managing Partner, Aisling Capital• Amy Comstock Rick, Chief Executive Officer, Parkinson's Action Network• Christian Loucq, PATH Malaria Vaccine Initiative
Brain Developmental
Disorders
Translating the mGluR Theory into Novel Therapeutics
Scientific Discovery
Druggable Targets
Efficacy in Model System
Candidate Drug
IND-enabling Research
Human Trials
Seaside Therapeutics Model
• Venture Philanthropy Seed Funding
• Core Competency in Translational Medicine
• Collaborative Business Model– Foundations – FRAXA, Autism Speaks, NFXF
– Merck & Co, Inc. – R&D Collaboration
– NIH UO1 Translational Research Cooperative Agreement• NIMH, NICHD, BPCA, NINDS, FRAXA & Autism Speaks
– Baylor Medical Center – Behavioral Research
– Vanderbilt University – Drug Discovery
– Correlagen Diagnostics – Companion Diagnostic
Basic Research
Prototype Design or Discovery
Preclinical Development
Clinical DevelopmentFDA Filing/ Approval &
Launch Preparation
The Development Pipeline and Valley of Death
Basic Research
[Mostly NIH Funded]
Prototype Design or Discovery
Preclinical Development
Clinical Development[Mostly Large Pharma]
FDA Filing/ Approval &
Launch Preparation
The Development Pipeline and Valley of Death
[Inconsistent Funding]
[Inconsistent Funding]
The Development Pipeline and Valley of DeathVarious Solutions
Prototype Design or Discovery
Preclinical Development
Clinical Development[Mostly Large Pharma]
FDA Filing/ Approval &
Launch Preparation
Private Foundation Research
NIH - SBIR
Venture Philanthropy
[Inconsistent Funding]
[Inconsistent Funding]
NIH – CTSA’s
TATRC
Basic Research
[Mostly NIH Funded]
TRND
